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In the last years an increasing number of subjects experienced respiratory failure and under-
went tracheostomy. The aim of the present study was to analyze tracheal aspirates from the
inflammatory point of view. Samples were collected from 38 consecutive tracheostomized
patients: 13 COPD, 6 with neurologic disorders and 19 with other different causes of respiratory
failure. We analyzed cells and soluble mediators related to inflammation and/or infection. We
also compared results obtained in the tracheal aspirate of COPD patients with the same deter-
mination in the sputum of another group of non-tracheostomized COPD patients (nZ 41).
Regardless of the underlying diagnosis, most of the samples were Pseudomonas aeruginosa
positive and cells and soluble mediator did not differ. Treatment with steroids was associated
with lower amount of total cells, neutrophils and lymphocytes, whereas treatment with antibi-
otics was not. Tracheal aspirate neutrophils correlated with PaCO2 values; neutrophils and
eosinophils correlated with their percentages in blood. As compared with sputa obtained from
another group of culture-positive non-tracheostomized COPDs, tracheal aspirates showed
similar cell count, proportions of inflammatory cells, and infection/inflammatory mediators.Immunology Unit, Fondazione Salvatore Maugeri, I.R.C.C.S., Via Salvatore Maugeri 10, 27100 Pavia,
ax: þ0039 0382 592086.
sm.it (P. Pignatti).
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202 P. Pignatti et al.Table 1 Characteristics of the p
Age (yrs, range)
Gender m/f
Type of tracheostomy
(percutaneous/surgical)
Mechanical ventilation (yes/no)
Steroid therapy (yes/no)
Antibiotic therapy (yes/no)
Time from
tracheostomy (days, range)
PaO2
PaCO2
Data are expressed as median (rang
a Patients included in the neurolo
(nZ 2), myastenia gravis (nZ 1).
b Patients included in the miscella
(nZ 1), obesity (nZ 3), Von HippelIn conclusion tracheal aspirates presented high amounts of viable cells and soluble mediators
independently to the cause of respiratory failure leading to tracheotomy and they represent
suitable specimens to study infection/inflammation interactions.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Tracheostomy is an invasive procedure aimed at providing
a secure airway to ventilate and aspirate the patient in the
critical care setting. Over the last decades many factors
favoured an increased use of this procedure: the intro-
duction of the percutaneous procedure to perform trache-
otomy, the possibility to connect patients to user-friendly
bed-side ventilators available also for long-term domiciliary
care, the increase in the number of patients with end-stage
respiratory diseases, and the emerging problem of patients
with neuro-degenerative disorders and of patients with
permanent damage after a neurological, neurosurgical or
traumatic event.1e3 All of these factors lead to increased
numbers of tracheostomized patients and caring for these
patients is becoming an important issue in rehabilitation
and chronic care facilities as well as in the home care
setting.
Apart from early complications and side-effects, in
patients with chronic tracheostomy, there are many other
common complications, primarily airway colonization and
infection.4 In this context, tracheostomy represents
a model to study hostebacteria interaction and a particular
form of airway inflammation, mainly affecting the large
airways and causing chronic injury of the mucosa. Inter-
estingly, this model of hostebacteria interaction can be
studied in different categories of patients since, in clinical
practice, tracheostomy is applied to different patients with
respiratory failure: those with an underlying respiratory
diseases (e.g. COPD) and those affected primarily by non-atients enrolled.
Total (nZ 38) COPD
73.5 (44e91) 78.0
13/25 5/8
27/11 7/6
8/30 0/13
18/20 8/5
11/27 4/9
53 (7e1519) 49
71.0 (42.0e100) 74.8
41.1 (27.5e87.0) 42.2
e).
gical disorder group: Guillan-Bar
neous disorder group: pneumonia
Lindau S. (nZ 1), post-abdominarespiratory diseases (e.g. neurological). Thus, the study of
tracheal aspirates in tracheostomized patients could
provide clues to the pathways of airway inflammation in
this particular setting, information that could prove useful
also for the clinical management of tracheostomized
patients. In contrast with this concept, only preliminary
anecdotal data on tracheal aspirate analysis is available in
a limited number of patients.5
Aim of our study was to evaluate the cellular, microbi-
ological and molecular components of tracheal aspirates
and to compare these characteristics in groups of chronic
trachostomized patients with different underlying diseases
and conditions. Our goal is to evaluate the possible role of
tracheal aspirate samples as a biological tool, with a focus
first on the relationship among airway inflammation, tra-
cheosotmy and bacterial colonization/infection, and
hopefully in the future on applications related to the clin-
ical status of tracheostomized patients.
Material and methods
Patients
We enrolled 38 consecutive tracheostomized patients: 13
COPDs, 6 subjects with neurological and 19 with mis-
cellaneous disorders (footnote Table 1). Inclusion criteria
consisted in tracheotomy with/without O2 or mechanic
ventilation, exclusion criteria were an ongoing pneumonia.
To compare data between tracheal aspirate and induced
sputum specimens another group of non-tracheostomized(nZ 13) Neurological
disorders (nZ 6)a
Miscellaneous
disorders (nZ 19)b
(64e87) 69.8 (55e83) 72.0 (44e91)
1/5 7/12
4/2 16/3
2/4 6/13
0/6 10/9
0/6 7/12
(18e1519) 43 (20e95) 61 (7e180)
(53.6e100) 67.5 (42.0e99.0) 71.0 (61.8e87.0)
(33.6e87.0) 39.5(33.0e56.0) 41.0 (27.5e65.0)
re` S. (nZ 2), polymiositis (nZ 1), amyotrophic lateral sclerosis
(nZ 8), kyphoscoliosis (nZ 3), Pickwick S. (nZ 1), septic shock
l surgery (nZ 1), vocal cord paralysis (nZ 1).
Tracheostomy and related hostepatogen interaction are associated with airway inflammation 203COPD patients (nZ 41) were enrolled. Sputum was induced
following international guidelines.6 The study was approved
by the Maugeri Foundation Ethical Committee and all
participants gave informed consent.
Tracheal aspirates
Tracheal secretions were obtained through aspiration with
a sterile catheter in the cannula. To standardize the
collection of specimens we performed a kinetic in 10
patients. Samples were collected at 8, 12 am and 4 pm and
cell viability, total and differential cell count were evalu-
ated. Once demonstrated that the time of collection did
not affect cell results, we collected all specimens at 10 am
after a cleaning procedure at 8 am to eliminate the night-
mucus. Tracheal aspirate samples, which appeared as
a unique homogeneous plug, were processed with 0.1%
dithiothreitol as previously reported.7 Cytospins were dyed
with Diff-Quick (Dade Diagnostika GmbH, Unter-
scheibheim). Cell viability, total and differential cell count
were assessed by microscope.
Tracheal aspirates were microbiologically analyzed with
blood and chocolate agar (bioMerieux sa, Marcy-l’Etoile, F)
after dithiothreitol fluidification. The semi quantitative
charge was converted in approximate CFU/ml.
Soluble mediators
SP-A, SP-D and fibronectin concentrations were measured
respectively by an ‘‘inhibition’’ and by a ‘‘sandwich’’
E.L.I.S.A as previously described.8,9 Matrix Metal-
loproteinase-9 (MMP-9) was determined by an immunoassay
according to manufacturer’s instructions (Amersham Biosci-
ences, Buckinghamshire, UK). The multiplex bead-based test
(Bio-plex cytokine assay, BioRad Laboratories Inc., Hercules,
CA, USA), was employed for the simultaneous determination
of Interleukin (IL)-2, IL-5, IL-6, IL-10, Tumor Necrosis Factor
(TNF)-a and Granulocyte Macrophage-Colony Stimulating
Factor (GM-CSF). Data were obtained and analyzed with Bio-
Plex Manager 4.0 software in the Laboratory of Industrial
Toxicology of the University of Parma, Italy.
To measure the concentration of LL-37, plates (F96 Cert
Maxisorp, Nunc, Wiesbaden, Germany) were loaded with
standards or samples and incubated at 37 C overnight and
allowed to dry. After washing and blocking with 0,1%
gelatin/PBS, a monoclonal antibody against LL-37 (clone 1-
1c12, Hycult/Sanbio, Germany) was added for 1 h at RT. For
detection a HRP-labeled anti-mouse antibody (GE Health-
care, Uppsala, Sweden) was used and developed with TMB
substrate solution. Synthetic LL-37 (Charite, Berlin, Ger-
many) was used as standard.
To measure the concentration of hBD2, plates were
coated with a polyclonal rabbit antibody against hBD210 and
blocked with 0.1% gelatin/PBS. After incubating the plate
overnight with samples or standards, it was incubated with
a detection antibody (anti-hBD2, AB9871, Abcam, 1:1000),
then a HRP labeled anti-goat antibody (1:40000, Sigma,
Germany) was added, and developed with TMB substrate
solution. Data were obtained and analyzed in the Depart-
ment of Internal Medicine e Respiratory Diseases, Marburg,
Germany.Statistical analysis
Data were expressed as median and range or as mean SD
when indicated and analyzed using ManneWhitney U test.
Correlations were assessed with Spearman’s rank test.
p Values< 0.05 were considered as significant. Repetitive
analysis were compared with ANOVA test. Analysis was
performed with Statistica for Window (Stat.Soft, Inc.1993).
Results
Patients’ characteristics
Patients enrolled in the study were tracheostomized for
respiratory distress and failure determined by different
causes: 13 COPD, 6 neurological disorders and 19 miscel-
laneous disorders. The specific diseases of patients in the
neurological and miscellaneous group are shown in the note
of Table 1. The average time elapsed from tracheotomy and
tracheal aspirate analysis was 53 days (median, 7e1519
days, range). At the time of the study 8 out of 38 patients
were mechanically ventilated, 18 patients were on corti-
costeroid treatment (3 systemic, 11 inhaled, 4 systemic and
inhaled) and 11 were on antibiotic therapy. Other patients’
characteristics are shown in Table 1.
Kinetic of tracheal aspirate collection
The samples at different time points presented comparable
results for both total cells harvested and cell distribution,
data not shown. In order to standardize the collection and
to avoid different time aspirating procedure between
patients, we collected each sample at 10 am.
Total cells and differential cell distribution
Tracheal aspirates collected in 38 patients presented high
viability and a cell population primarily constituted by
neutrophils (Table 2).Whenwe divided patients according to
the disease leading to tracheostomy, no difference in total
and differential cell count was found among patients with
COPD, neurological or miscellaneous disorders. Similarly, no
influence was demonstrated on total and differential cell
count by the type of technique to obtain tracheostomy
(percutaneous vs surgical 27/11), the presence or absence of
MV (8/30), antibiotic therapy (11/27), time elapsed from the
tracheostomy procedure and type of bacteria colonizing the
airways. In contrast, patients treated with steroids (nZ 18)
presented lower total cells/mg, neutrophils/mg and
lymphocytes/mg comparedwith untreated patients (nZ 20)
Fig. 1 (pZ 0.03, pZ 0.04, pZ 0.01 respectively).
Furthermore, the amount of neutrophils and eosinophils
in the tracheal aspirates correlated with their percentages
in the blood (rZ 0.33, pZ 0.045 and rZ 0.67,
pZ 0.000006 respectively).
Soluble mediators
The data obtained are shown Table 3. DTT did not affect
soluble mediator evaluation as demonstrated in spiking
Table 2 Total and differential cells in tracheal aspirate samples in all the patients enrolled and divided in groups.
Total patients (nZ 38) COPD (nZ 13) Neurological
disorders (nZ 6)
Miscellaneous
disorders (nZ 19)
Viability (%) 90.9 (70.0e97.6) 90.9 (82.3e94.7) 86.5 (82.3e91.7) 92.8 (70.0e97.6)
Macrophages (%) 6.2 (0.6e26.0) 6.4 (0.6e16.8) 3.5 (0.9e82.) 6.7 (1.9e26.0)
Neutrophils (%) 90.0 (69.5e98.6) 86.4 (74.3e98.5) 93.1 (82.2e98.6) 90.9 (69.5e96.3)
Eosinophils (%) 0.2 (0.0e6.0) 0.4 (0.0e6.0) 0.1 (0.0e1.6) 0.0 (0.0e1.8)
Lymphocytes (%) 1.6 (0.0e7.9) 1.6 (0.0e7.9) 1.1 (0.2e2.6) 1.6 (0.0e5.0)
Epithelial cells (%) 0.7 (0.0e10.0) 2.7 (0.0e5.6) 1.7 (0.0e7.6) 0.6 (0.0e10.0)
Cell/mg 12760 (1120e246400) 8400 (2848e246400) 29380 (9440e112000) 18200 (1120e218400)
Macrophages/mg 940 (20e6025) 448 (20e3696) 1001 (330e2023) 1080 (42e6025)
Neutrophils/mg 11477 (1039e242704) 7286 (2429e242704) 24498 (8713e110432) 16780 (1039e210100)
Eosinophils/mg 15 (0e413) 47 (0e413) 10 (0e151) 0 (0e216)
Lymphocytes/mg 185 (0e2836) 139 (0e663) 220 (79e560) 206 (0e2839)
Epithelial cells/mg 111 (0e1441) 88 (578) 285 (0e1441) 103 (0e1200)
Data are expressed as median (range).
*p< 0.05  treated vs untreated patients
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Figure 1 Tracheal aspirate total cells (open bars), neutro-
phils (dotted bars) and lymphocytes (dashed bars) in patients
treated and untreated with corticosteroids. Data are repre-
sented as meanþ SD.
204 P. Pignatti et al.experiments (data not shown). Fibronectin, IL-6 and TNF-
a were the most representative soluble mediators detected
in tracheal aspirate samples. No difference in soluble
mediators was found among tracheal aspirates from COPD
patients and subjects with neurological or miscellaneous
disorders. A tendency toward higher IL-6 levels in tracheal
aspirates of COPD patients was present but the difference
with the other groups was not statistically significant. No
influence was demonstrated on soluble mediators levels by
the type of technique used to obtain tracheosotomy
(percutaneous vs surgical), the presence or absence of MV,
antibiotic or steroid therapy, time elapsed from the
tracheostomy procedure and type of bacteria detected in
the airways. Fibronectin levels correlated with IL-6
(rZ 0.66, pZ 0.000008) and the concentrations of the two
surfactant proteins SP-A and SP-D were associated (rZ 0.9,
pZ 0.00000) Fig. 2 (panel A and B). GM-CSF levels were
correlated with IL-2, IL-6 and IL-10 (rZ 0.58, pZ 0.0012;
rZ 0.59, pZ 0.00046 and rZ 0.4, pZ 0.04 respectively).
IL-5 levels were significantly correlated with the
percentage of eosinophils in the tracheal aspirates of COPD
patients (rZ 0.9, pZ 0.001).
Microbiology and innate immunity data
The microbiological analysis was performed in 34 out of 38
tracheal aspirate samples: 30 positive and 4 negative.
Pseudomonas aeruginosa was the most prominent microbial
agent identified in the tracheal aspirates analyzed
(P. aeruginosa pos vs tot analyzed: 21/34), particularly
among the COPD ones (61.5%), and in the miscellaneous
group (68.7%) (Table 4). In the neurological group 40.0% of
the tracheal aspirates analyzed resulted P. aeruginosa
positive. Considering that most of the tracheal aspirates
were microbiologically positive we evaluated in these
samples the presence of two anti-microbial peptides hBD2
and LL-37. They were detectable in all the samples
evaluated (Table 3). Steroid and antibiotic treatments did
not affect hBD2 and LL-37 levels. Patients with a positive
tracheal aspirate for P. aeruginosa tended to have higher
hBD2 levels but the difference did not reach the statisticalsignificance (in P. aeruginosa positive samples, median
hBD2: 45.5 range 2.5e93.0 ng/ml, in P. aeruginosa negative,
median: 12.5, range 0.1e91 ng/ml) hBD2 levels negatively
correlated with the percentage of eosinophils in tracheal
aspirates (rZ0.44, pZ 0.03) whereas LL-37 levels were
associated with the amount of neutrophils in the tracheal
aspirates (rZ 0.51, pZ 0.01). Furthermore, MMP-9 levels
were negatively associated with LL-37 (rZ0.91,
pZ 0.000000) (Fig. 2, panel C).
Correlations with indexes of chronic respiratory
failure
Considering all the patients enrolled, there was a weak
correlation between the percentage of neutrophils in
tracheal aspirates and PaCO2 values (rZ 0.33, p< 0.05).
Furthermore, in patients with COPD as underlying diag-
nosis, there was a negative correlation between MMP-9
levels in tracheal aspirates and PaO2 (rZ0.64, pZ 0.02).
IL-10 levels were negatively correlated with ESR (0.42,
pZ 0.02).
Table 3 Soluble mediators in tracheal aspirate samples.
Total patients
(nZ 38)
COPD (nZ 13) Neurological
disorders (nZ 6)
Miscellaneous
disorders (nZ 19)
Cytokines and inflammatory mediators
IL-2 (pg/ml) 1.4 (0.2e27.0) 1.4 (0.2e2.4) 0.2 (0.2e2.4) 2.4 (0.2e27.0)
IL-6 (pg/ml) 165.6 (5.3e6865.8) 298.1 (37.8e1171.2) 76.4 (27.4e484.4) 173.1 (5.3e6865.7)
IL-10 (pg/ml) 4.2 (0.3e55.3) 5.7 (0.3e33.0) 4.2 (1.0e14.6) 4.3 (1.4e55.3)
GM-CSF (pg/ml) 3.9 (0.3e39.9) 4.3 (0.5e10.1) 3.0 (1.0e5.8) 3.8 (0.3e40.0)
TNF-a (pg/ml) 382.8 (19.5e1843.3) 231.2 (19.5e1233.3) 396.2 (184.2e556.1) 660.0 (32.2e1843.3)
IL-5 (pg/ml) 18.2 (0.6e117.1) 18.7 (9.2e117.1) 15.0 (10.6e19.4) 12.8 (0.6e24.1)
MMP-9 (ng/ml) 14.5 (1.6e61.9) 17.7 (4.7e64.9) 12.3 (5.5e27.5) 17.4 (1.6e43.6)
Anti-microbial peptides
hBD2 (ng/ml) 45.5 (0.1e93.8) 49.7 (1.2e72.4) 10.0 (6.4e91.6) 45.5 (0.1e93.8)
LL-37 (ng/ml) 1326.5 (209.8e4014.8) 663.6 (271.3e3331.3) 403.9 (209.8e3707.4) 2125.6 (291.1e4014.8)
Other soluble compounds
Fibronectin (ng/ml) 648.0 (119.2e5760) 708.0 (233.6e2904.0) 366.0 (225.6e1472.0) 704.0 (119.2e5760.0)
SP-A (ng/ml) 81.6 (6.4e409.6) 111.6 (30.6e347.2) 33.4 (6.4e155.2) 61.0 (17.7e409.6)
SP-D (ng/ml) 75.9 (6.4e735.2) 97.6 (6.4e370.4) 53.4 (6.4e212.8) 74.2 (6.4e735.2)
Data are shown as median (range).
Tracheostomy and related hostepatogen interaction are associated with airway inflammation 205Comparison between tracheal aspirate and induced
sputum specimens
Considering the tracheal aspirate a sample candidate to
represent a particular form of airway inflammation,
involving primarily the large airways and associated to
a chronic injury of the mucosa and to a hostebacteria
interaction, we compared cells and soluble mediators from
tracheal aspirates with those found in sputum samples
which might resemble them most closely. In fact, induced
sputum is considered to be primarily derived from large
airways.6 This analysis was performed enrolling anotherB
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Figure 2 Correlation between fibronectin and IL-6 levels (pane
tracheal aspirate samples (panel C).group of non-tracheostomized COPD patients (nZ 41, M/F:
32/9; mean age: 65.6 10.8; mean FEV1: 64.8 24.6). 16/
41 were on steroid therapy before sputum induction and
16/41 had a sputum positive culture. The comparison
between tracheal aspirates and induced sputum, showed
that tracheal aspirates had higher percentages of neutro-
phils and lower percentages of eosinophils (pZ 0.02 and
pZ 0.009). However, when out of non-tracheostomized
COPD patients, we selected only those with microbiologi-
cally positive sputum (nZ 16), no difference was found in
the total and differential cell count between the two types
of specimens (Fig. 3). Among the soluble mediators0
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Table 4 Microbiological analysis of tracheal aspirate samples.
Group (pos/evaluated) (P. aerug pos/tot pos) Isolated microorganisms n
COPD (11/13) (8/11) Pseudomonas aeruginosa 4
P. aeruginosa, Providencia rettgeri 1
P. aeruginosa, Proteus mirabilis 1
Proteus mirabilis, P. aeruginosa, MRSA 1
P. aeruginosa, P. stutzeri, Providencia rettgeri 1
Candida albicans 3
Neurological group (4/5) (2/4) Pseudomonas aeruginosa 1
P. aeruginosa, MRSA 1
Acinetobacter baumannii 1
Enterobacter aerogenes, MRSA, Candida glabrata 1
Miscellaneous group (15/16) (11/15) Pseudomonas aeruginosa 5
P. aeruginosa, Klebsiella pneumoniae 1
P. aeruginosa, MRSA 2
P. aeruginosa, MRSA, Klebsiella pneumoniae 1
P. aeruginosa, Stenotrophomonas malt, MRSA 1
P. aeruginosa, Serratia marcescens 1
Providencia stuartii 1
MRSA 2
Serratia marcescens, Burkholderia cepacia 1
MRSAZmethicillin-resistant Staphylococcus aureus.
206 P. Pignatti et al.evaluated only IL-6 was significantly higher in tracheal
aspirates than in sputa of COPD patients (pZ 0.015), but
again when we selected only culture-positive samples no
difference was found between the two types of specimens,
Fig. 4.
While tracheal aspirates of patients treated with
steroids presented lower total cells/mg, neutrophils/mg
and lymphocytes/mg compared with untreated patients,
cells in sputum samples were comparable between treated
(nZ 16) and untreated subjects (nZ 25).
Discussion
In this study by examining the tracheal aspirates obtained
by an unselected cohort of tracheostomized patients, we
demonstrated that: a) the majority of the samples were0,1
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Figure 3 Cells in total sputum samples (open bars), in positiv
specimens (dashed bars) of COPD patients. Data are expressed aspositive for P. aeruginosa, regardless of the underlying
diagnosis; b) tracheal aspirates comprised a large number
of viable cells, mostly neutrophils; c) neither underlying
diagnosis, nor ongoing MV or antibiotic therapy or time
elapsed from the tracheostomy procedure influenced the
tracheal aspirate cell composition; d) ongoing therapy with
glucocorticoids was associated with lower number of
total cells, neutrophils and lymphocytes; and e) tracheal
aspirates resemble sputum samples in COPDs as concerns
cell count, proportion of inflammatory cells, and infection/
inflammatory mediators.
Previous studies on tracheal aspirates came from
pre-term infants focusing on inflammatory mediators,
predictors of outcome.11e13 To the best of our knowledge,
only one study on a few adult tracheostomized subjects
addressed inflammation in aspirates.5epithlymphoeos
sputum tot
sputum pos cult
tracheal aspirate
p <0.05
e culture sputum samples (grey bars) and tracheal aspirate
meanþ SD.
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Figure 4 Soluble mediators in total sputum samples (open bars), in positive culture sputum samples (grey bars) and tracheal
aspirate specimens (dashed bars) of COPD patients. Data are expressed as meanþ SD.
Tracheostomy and related hostepatogen interaction are associated with airway inflammation 207The method of tracheal aspirate processing we used,
that was standardised for induced sputum, provided reli-
able results demonstrated by the correlation we found
between peripheral and tracheal aspirate neutrophils and
eosinophils and by the association in COPDs between
tracheal aspirate IL-5 and eosinophils. All the specimens
presented a high amount of viable cells, mainly neutrophils.
This result was reported also for the 6 patients previously
described by Palmer et al.,5 although with lower neutrophil
percentages, probably as a consequence of the different
way of tracheal aspirate collection and handling.
What could be the role of neutrophils in the large
airways of tracheostomized patients? Neutrophils are the
most important cells of the innate immune system
recruited in the site of microbial attack and the soluble
mediators found in the tracheal aspirates favour the
survival of these cells inhibiting their apoptosis. GM-CSF,
a potent regulator of neutrophil survival,14 found in the
aspirates of our patients could explain increasing neutro-
phil survival and the correlation between GM-CSF and IL-2,
IL-6 and IL-10 demonstrate the activation of a pro/anti-
inflammatory cytokine network.
Furthermore, the detrimental effect of neutrophil accu-
mulation in this microenvironment was strengthened by the
correlation found between tracheal aspirate neutrophils and
PaCO2 levels. We found comparable results in tracheal aspi-
rates coming from different patients, i.e. COPDs, neurolog-
ical or other patients, demonstrating that independently
from the conditions which have determined the tracheos-
tomy, the resulting inflammatory picture is common and
‘‘self-feeding’’. If so, this sample would represent a suitable
tool to study and evaluate other types of pathological
processes somehow unrelated to diseases or therapies but
more closely dependant on the interaction of the host
immune and inflammatory reactions toward a ‘‘double-hit’’
type of injury: mechanical and microbiological.
Among the factors evaluated as possible source of
changes in tracheal aspirate composition, only therapy with
steroids showed such an effect, decreasing total cells,
neutrophils and lymphocytes/mg, particularly in the COPD
group in which most of the patients were steroid-treated.
These data are consistent with those previously reported in
tracheal aspirates of pre-term infants treated with
dexamethasone.15No effect of antibiotics was found on tracheal aspirates
in contrast with Palmer et al. who demonstrated an evident
short-term (6 h burden) effect of antibiotics on the volume
of tracheal aspirate collected and on neutrophils.5 Our data
suggest that antibiotic treatment is not sufficient to down-
regulate mucosal inflammation associated with infection/
colonization by bacteria, even if more data are needed,
particularly tracheal aspirate analysis before and after
antibiotic treatment, to better clarify this aspect.
The time elapsed between tracheotomy and tracheal
aspirate collection, comparable in the three groups of
subjects, did not affect cells and soluble mediators evalu-
ated. This may have several implications: first, this time-
period could probably have been enough to make the
microenvironment characteristic of microbiological coloni-
zation prevail over those determined by the underling
diseases; second, the type of injury and repair and/or
defence mechanisms of large airways may be conserved
and remain similar also in patients with different respira-
tory disorders.
Endotracheal intubation predisposes to infections for
different reasons: endotracheal tube can have direct
effects on airways and on reduction of local host defences,
reduced mucociliary function, stagnation of mucus,
increase in entrance of bacteria.16 Most of the tracheal
samples evaluated presented P. aeruginosa colonization as
previously reported in adults and in children17e19 and no
microbiological difference was found in patients with
different underlying diseases, as previously reported by
Lusuardi et al.20 Recently Giannoni et al. demonstrated
that surfactant protein A and D enhance pulmonary clear-
ance of P. aeruginosa.21 We found that these two proteins
are present in tracheal aspirates, and their levels were
associated. However, no difference was found in SP-A and
SP-D levels between patients with or without P. aeruginosa
colonization.
hBD2 and LL-37, two anti-microbial peptides present in
the respiratory tract22 and involved in the innate immunity
were detected in the tracheal aspirates. LL-37 levels
correlated with the amount of neutrophils confirming the
strict dependence between this peptide, stored in neutro-
phil granules, and proteolitic enzymes, i.e. elastase,
produced by neutrophils which can activate LL-37.23,24 LL-
37 is also chemo-attractant for neutrophils and it inhibits
208 P. Pignatti et al.neutrophil apoptosis25 increasing the amount of neutrophils
accumulated in the airways. We found that LL-37 levels
were negatively correlated with MMP-9 ones suggesting that
MMP-9 expressed by airway neutrophils, macrophages and
also by bronchial epithelial cells, can also degrade LL-37.
Furthermore, hBD2 which has been detected in tracheal
aspirates is highly inducible by epithelial cells upon contact
with P. aeruginosa, or by endogenously produced TNF-a and
IL-1b.26
To better characterize tracheal aspirates as specimen,
we compared tracheal aspirates of COPDs with induced
sputa collected in another group of non-tracheostomized
COPDs. Cell amount and soluble mediator levels in the two
types of samples were similar. Only IL-6 was higher in
tracheal aspirates than in sputa of COPDs, but when we
compared microbiologically positive sputa and aspirates,
this difference was not statistically significant anymore,
thus confirming the strict relationship between IL-6 and
airway infection. Furthermore, these data demonstrated
that microbial infection is one of the leading cause deter-
mining airway inflammation and cell recruitment in
tracheal aspirate and sputum samples.
In conclusion we demonstrated that tracheal aspirates,
regardless of the cause of tracheostomy, mainly reflect the
inflammatory/infective airway microenvironment estab-
lished after tracheotomy. Many inflammatory/infectious
mediators have been detected in these samples which
could be target of anti-inflammatory intervention. Results
obtained offer plenty of opportunity to study an in vivo
model of hostebacteria interaction both from the immu-
nological and from the microbiological point of view.
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